Should I Buy SRPT? SRPT 2026 Analysis

Should You Buy Sarepta Therapeutics Inc (SRPT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

20.760

1 Day change

-3.08%

52 Week Range

64.800

Analysis Updated At

2026/04/17

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Sarepta Therapeutics Inc (SRPT) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock faces significant financial challenges, negative sentiment from analysts, and a lack of strong positive catalysts. Additionally, hedge funds are selling, and there are no proprietary trading signals indicating a strong buy opportunity.

Technical Analysis

The technical indicators are mixed. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD histogram is negative and expanding downward, and the RSI is neutral at 44.017. The stock is trading near its support level (S1: 21.065), but there is no clear upward momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low option volume put-call ratio of 0.18 suggests bullish sentiment in the short term. However, the open interest put-call ratio of 0.84 indicates a more balanced outlook, with no strong conviction from options traders.

Technical Summary

Sell

Buy

Positive Catalysts

and its upcoming sNDA submission for Amondys/Vyondys, which could remove regulatory risks. Additionally, the stock has shown some early-stage promise in muscular dystrophy treatments.

Neutral/Negative Catalysts

H.C. Wainwright and other analysts highlight significant risks with Sarepta's Elevidys program, including the potential for failure in Phase 3 trials. Hedge funds are aggressively selling the stock, and the company's financial performance has deteriorated significantly. The stock also faces competition from Capricor's upcoming FDA decision on Deramiocel, which could impact Sarepta's market share.

Financial Performance

Sarepta's Q4 2025 financials are concerning, with revenue down -32.73% YoY, net income down -277.84% YoY, EPS down -304.55% YoY, and gross margin dropping to 47.15% (-40.92% YoY). These metrics indicate significant financial struggles and limited growth potential in the near term.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is predominantly negative. Several firms, including H.C. Wainwright, Deutsche Bank, and Citi, maintain Sell ratings with low price targets, citing risks in Sarepta's core programs and financial outlook. While a few analysts like Wedbush and Oppenheimer are optimistic about long-term prospects, their price targets remain modest, and their optimism is tempered by early-stage data and high uncertainty.

18 Analyst Rating

Wall Street analysts forecast SRPT stock price to fall

4 Buy

10 Hold

4 Sell

Hold

Current: 21.420

Low

Averages

20.8

High

Current: 21.420

Low

Averages

20.8

High

H.C. Wainwright

Mitchell Kapoor

Sell

maintain

AI Analysis

2026-04-16

New

Reason

H.C. Wainwright

Mitchell Kapoor

Price Target

AI Analysis

2026-04-16

New

maintain

Sell

Reason

H.C. Wainwright analyst Mitchell Kapoor reiterates a Sell rating on Sarepta (SRPT) with a $5 price target saying Roche's (RHHBY) new placebo-controlled Phase 3 study raises the risk that Elevidys fails the North Star Ambulatory Assessment efficacy test again. The EMBARK study already failed to show statistical significance on NSAA, and Roche is trying again, the firm points out. Roche is now putting Elevidys "back into another randomized test that could further crack the external-control argument if NSAA misses again," the analyst tells investors in a research note. H.C. Wainwright believes this creates limited upside for Sarepta and meaningful downside for the U.S. franchise that still drives the shares. Sarepta's core revenue stream is the U.S. Elevidys business, not Europe, the firm contends.

RBC Capital

Sector Perform

maintain

$18 -> $19

2026-04-07

Reason

RBC Capital

Price Target

$18 -> $19

2026-04-07

maintain

Sector Perform

Reason

RBC Capital raised the firm's price target on Sarepta to $19 from $18 and keeps a Sector Perform rating on the shares as part of the firm's broader research note previewing Q1 results in Biotech. Seasonal headwinds around gross/net, reimbursement resets, and fewer selling days may be exacerbated in Q1 by weather impact, particularly for launching and in-clinic products, but the robust return of M&A, coupled with clarity on limited tariff/Most Favored Nation drug pricing impacts, could help offset both this and broader macro volatility while keeping sector perceptions favorable, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SRPT

Unlock Now

SRPT Should I Buy

SRPT Should I Buy

Should You Buy Sarepta Therapeutics Inc (SRPT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch